Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Parkinson's disease in patients with type 2 diabetes
ACTRN12620000627954Phase 4Recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Jun 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of exenatide in Parkinson's disease (PD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by St Vincent's Hospital Sydney. Primary endpoint: Change in motor symptoms of Parkinson's disease as determined by OFF-MED UPDRS part 3 scores. Started Jun 2020; status: recruiting.
02
Drugs
exenatide
03
Conditions
Parkinson's disease (PD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12620000627954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000627954.